Home
Stampa
HomeStampa
HomeStampa
13:30 - 16:00 | Special Session
Incontro Scuole RaccontART
16:30 - 17:15 | Satellite Symposium
Reflecting on treatment strategies to achieve long-term treatment success in HIV
17:20 - 20:00
ICAR 2021 Opening Session
20:00 - 22:30
ICAR 2021 Welcome Reception
13:30 - 16:00 | Pre-Conference advanced course
Focus on molecular surveillance of epidemic/pandemic viral infections
13:30 - 16:00 | Pre-Conference advanced course
New opportunities in HIV and prevention: towards achieving controlled risk
13:30 - 16:00 | Pre-Conference advanced course
Long-acting therapies in HIV and bacterial infections: the nurse role
Special Session
Incontro Scuole RaccontART
Special Session
Incontro Scuole RaccontART
VII Edizione del concorso RaccontART, il contest artistico promosso tra gli studenti delle scuole superiori. Gli Istituti scolastici in gara: I.I.S. Ettore Majorana, San Lazzaro di Savena (BO) - I.S. Puecher-Olivetti, Rho (MI) - Liceo Artistico Giuseppe Terragni - Centro Studi Casnati, Como - Liceo Artistico Simone Weil, Treviglio (BG) - Liceo Linguistico Giovanni Pascoli, Firenze
Chairs: A. Caraglia, F. Ceccherini - Silberstein, A. Lazzarin
| 13.30 - 13.40 | Benvenuto dei Presidenti ICAR 2021: G. V. Calvino, M. R. Capobianchi, A. M. Cattelan, C. Mussini |
| 13.40 - 14.10 | Introduzione e presentazione della Giuria Artistica e Tecnico-Scientifica |
| 14.10 - 15.45 | Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici |
| 15.45 - 16.00 | Conclusioni |
Satellite Symposium
Reflecting on treatment strategies to achieve long-term treatment success in HIV
Con la sponsorizzazione non condizionante di: 
Satellite Symposium
Reflecting on treatment strategies to achieve long-term treatment success in HIV
To explore how current treatment strategies, an evolving ART landscape and renewed focus on evolving patient needs will drive changes in treatment goals and expectations among PLWH. The meeting will open with a short plenary presentation reviewing how current treatment strategies are able to meet goals and patient needs in the management of both treatment-naïve and treatment-experienced PLWH, with focus on late-presenters, rapid ART initiation and switching strategies for optimizing ART to achieve treatment success. This will be followed by an eye to the future with the innovative HIV pipeline. Finally, a panel-led discussion will facilitate the discussion around the benefits and potential drawbacks of individualized approaches to reach long-term treatment success.
Chairs: A.M. Cattelan, C. Mussini
Discussant: A. Gori
| 16.30 - 16.35 | Introduction
A.M. Cattelan, C. Mussini |
| 16.35 - 16.45 | Current treatment strategies to meet evolving needs in HIV naïve patients
A. d'Arminio Monforte |
| 16.45 - 16.55 | Current treatment strategies and long term safety in HIV switching patients
G. Di Perri |
| 16.55 - 17.05 | How Long acting and future drugs will address individual patient needs
A. Castagna |
| 17.05 - 17.15 | Round table with faculty panel. Reflecting upon today for change tomorrow: addressing issues to improve outcomes across the diverse patient populations
A. Gori |
ICAR 2021 Opening Session
ICAR 2021 Opening Session
Chairs: A. Antinori, G.V. Calvino, M.R. Capobianchi, A. Caraglia, A.M. Cattelan, F. Ceccherini - Silberstein, M.L. Cosmaro, A. Cossarizza, M. Galli, A. Lazzarin, C. Mussini
| 17.20 - 17.40 | Introducing ICAR 2021: authorities' welcome addresses |
| 17.40 - 18.00 | RaccontART contest Awards |
| 18.00 - 18.40 | Lecture "40 years of HIV pandemic, 40 years of progress in medicine"
G. Ippolito, M. Oldrini |
| 18.40 - 19.10 | Mauro Moroni Memorial Lecture "40 years of AIDS: sorrows and successful stories"
A. d'Arminio Monforte |
| 19.10 - 19.40 | Lecture "The challenging field of vaccine research"
R. Rappuoli |
| 19.40 - 20.00 | Closing remarks |
ICAR 2021 Welcome Reception
ICAR 2021 Welcome Reception
Pre-Conference advanced course
Focus on molecular surveillance of epidemic/pandemic viral infections
Pre-Conference advanced course
Focus on molecular surveillance of epidemic/pandemic viral infections
Genetic characterisation of viral genomes responsible for epidemic/pandemic episodes has been proven to be a powerful tool to understand outbreak transmission dynamics, spill-over events and to screen the mutations that potentially have an impact on transmissibility, pathogenicity and diagnostics. Sequence data can afford to monitor viral evolution and to timely identify potential markers of increased transmissibility, severity of disease or altered antigenicity. In addition, as the epidemic/pandemic evolves, these data become increasingly important in order to verify the match of the circulating variants with the response to vaccines and the possible emergence of antiviral resistance. By combining information of virus characteristics with clinical and epidemiological data, it is possible to plain public health interventions and to make outbreak control decisions.
Chairs: I. Abbate, I. Bon, C. Tincati
| 13.30 - 14.00 | Epidemic/pandemic viral infections: origin, spread and adaptation of new human viruses
G. Rossini |
| 14.00 - 14.30 | Tracing the infection transmission chains
F. Vairo |
| 14.30 - 15.00 | Spatio-temporal distribution of SARS-CoV-2 during COVID-19 pandemic
M. Chiara |
| 15.00 - 15.30 | SARS-CoV-2 variants and immune evasion
C. Tincati |
| 15.30 - 16.00 | Discussion on Course issues |
Pre-Conference advanced course
New opportunities in HIV and prevention: towards achieving controlled risk
Pre-Conference advanced course
New opportunities in HIV and prevention: towards achieving controlled risk
The first form of treatment for HIV is prevention. The concept of prevention includes the broader concept of an individual's sexual health. Science is making advances toward the goal of preventing HIV and therefore most sexually transmitted infections. The rationale for this course is to investigate the concept of sexual health particularly in " neglected" populations with limited access to health care systems, such as the migrant population. Secondly, scientific advances in HIV prevention will be analyzed with a focus on new strategies for pre-exposure prophylaxis and ongoing trials for an HIV vaccine. Vaccine trials have posed a new key concept, represented by the management of the in-trial patient, the sexually transmitted diseases that occur during the trial and the management of VISP (vaccine-induced seropositivity). Another extremely important way of prevention is the HIV-patient on treatment, and it is crucial in this setting to hear the voice of HIV-positive patients on treatment and with undetectable viral load.
Chairs: L. Badia, A. Bignardi, G. Cuomo, R. Rossotti
| 13.30 - 14.00 | High risk sexual behaviors and HIV/STDs cascade of care in migrants
V. Fiore |
| 14.00 - 14.30 | New PrEP strategies beyond F/TDF
E. Bruzzesi |
| 14.30 - 15.00 | In-treatment patient's experience
N. Frattini, M. Stizioli |
| 15.00 - 15.30 | Clinical management in ongoing HIV vaccine trials: key points and challenges
M. Menozzi |
| 15.30 - 16.00 | Discussion on Course issues |
Pre-Conference advanced course
Long-acting therapies in HIV and bacterial infections: the nurse role
Pre-Conference advanced course
Long-acting therapies in HIV and bacterial infections: the nurse role
The introducing of long-acting therapy in the clinical practice of Infectious Disease Units will bring positive implications in the management of chronic patients with HIV and bacterial infections. It will be required to reshape the organization of the clinics and consequently a new nursing care model have to be redefined. After forty years of fighting against HIV, the principal aim is the development of antiretroviral therapies capable to reduce the disease progression and slow down clinical manifestations. The use of long-acting therapy can leading to an improvement in therapeutic adherence. This is fundamental in daily clinical practice, especially for the nursing figure who is personally involved not only in the administration of the drug but also in patient's information and education. Moreover, the use of long-acting therapy in bacterial infections, patients could be treated in outpatient regimens or at home with an improvement in therapeutic efficacy and in the reduction of hospitalizations and healthcare costs.
Chair: M. Gatti
| 13.30 - 14.00 | HIV long-acting therapy: new nursing care model
E.M. Beretta |
| 14.00 - 14.30 | Long active drugs are an opportunity to improve adherence to care
S. Aliverti |
| 14.30 - 15.00 | Nursing management of Gram-positive infections
M. Luciano |
| 15.00 - 15.30 | Outpatient parenteral antibiotic treatment: the nurse role
M. Cornia |
| 15.30 - 16.00 | Discussion on Course issues |
09:00 - 10:00
Keynote Lectures
10:05 - 11:05 | Symposium
Antiviral immune control
11:10 - 12:10 | Sponsored Symposium
2DR: Evolving mindset, expanding experience
12:15 - 13:15 | Symposium
Pharmacology of antiviral drugs and vaccines
13.15 - 14.15 | Oral Poster
Foyer Auditorium - Oral Poster
14:15 - 15:15 | Sponsored Symposium
Continuous innovation for long-term treatment success
15:20 - 16:20 | Symposium
Behavioral and social impact of COVID-19 in PLWH
16:25 - 17:25 | Symposium
SARS-CoV-2 infection in persons living with HIV
17:30 - 18:30 | Symposium
Novel long-acting therapies for the treatment of Multidrug-Resistant (MDR) HIV-1 infection: let's go undetectable again
10:05 - 11:05 | Oral Communications
Clinical HIV
11:10 - 12:10 | Oral Communications
Coinfections and Hepatitis
12:15 - 13:15 | Oral Communications
Clinical HIV & Clinical COVID I
14:15 - 15:15 | Oral Communications
Epidemiology/Social sciences II
15:20 - 16:20 | Expert Meeting
Monoclonal antibodies and their role in COVID-19 patients: results and perspectives
16:25 - 17:25 | Expert Meeting
Vaccines roadmap: the humanity game-changer
17:30 - 18:30 | Symposium
Co-infections in 2021
10:05 - 11:05 | Oral Communications
Epidemiology/Social sciences I
11:10 - 12:10 | Expert Meeting
MDR pathogens in the COVID-19 era: experiences with Cefiderocol
12:15 - 13:15 | Expert Meeting
The first of a new generation NNRTI: the opportunity to get to the heart of PLWH
14:15 - 15:15 | Expert Meeting
Hyperinflammation and COVID-19: from research to clinical practice
15:20 - 16:20 | Expert Meeting
Roundtable New treatment options for heavily pretreated patients
16:25 - 17:25 | Oral Communications
Antiretroviral Therapy I
17:30 - 18:30 | Oral Communications
Clinical HIV & Clinical COVID II
11:10 - 13:00 | Meet the Community
40 years of HIV: reforming law 135/90 to achieve 2030 SDG and AIDS elimination
13:15 - 14:15 | Expert Meeting
ICONA-PROs in the real-life setting
16:25 - 17:25 | Oral Communications
Epidemiology/Social sciences III
Keynote Lectures
Keynote Lectures
Chairs: A. De Maria, A. Moznich
| 09.00 - 09.30 | Community services for vulnerable groups at the forefront during the COVID-19 pandemic. How to ensure sustainability?
D. Calzavara |
| 09.30 - 10.00 | Immune System biology to fight COVID-19
S. De Biasi |
Symposium
Antiviral immune control
Symposium
Antiviral immune control
The delicate balance between protective and pathogenetic processes during viral infections represents a key topic to be addresses in order to identify protective signature and viral/host targets for new treatments. In SARS-CoV-2 infection, the wide range of clinical presentations of COVID-19, ranging from asymptomatic to severe pneumonia, strongly supports a main role of host factors in defining the outcome of the infection. Accordingly, several studies described underlying immune-based pathogenic mechanisms characterized by a profound lymphopenia, an exacerbated inflammatory responses and a dysregulated innate and adaptive immune response. Early events after infection (Type-I IFN-s, innate immune cells activation, inflammatory storm) can represent the first critical step able to drive the generation of a sterilizing and long lasting immunity.
Chair: L. Lopalco
| 10.05 - 10.10 | Introduction |
| 10.10 - 10.20 | Maintening immunological memory in COVID-19 patients: the role of vaccination
A. Mazzoni |
| 10.20 - 10.30 | Interferon pathways in controlling HIV and COVID infections
C. Scagnolari |
| 10.30 - 10.40 | Exploring humoral immunity in COVID patients
G. Siracusano |
| 10.40 - 10.50 | Persistence of an intact HIV reservoir in CD4 T cell subtypes
E. Venanzi Rullo |
| 10.50 - 11.05 | Discussion on Symposium issues |
Sponsored Symposium
2DR: Evolving mindset, expanding experience
Con il supporto di: 
Sponsored Symposium
2DR: Evolving mindset, expanding experience
The life expectancy of people living with HIV (PLWHIV) is now close to the one of HIV negative people. This important milestone has been achieved thanks to the continuous evolution of antiretroviral therapy (ART), the basis of which continuous improvement placed on providing optimal therapeutic options for long-term management. In this context, ART therapy has evolved in the direction of 2-drug regimens (2DR), which, initially considered a new concept, today represent a reality in the embedded phase. In particular, dolutegravir (DTG) -based regimens are an important therapeutic option, both in the initial phase of treatment and in the switch from ARV. Starting from these assumptions, the session will focus on the evolution of the mindset in therapy management thanks to the solid evidence from the clinical studies available for DTG / 3TC and DTG / RPV. This evolution is associated with a growth of experience in clinical practice with the expansion of the use of DTG-based 2DRs in both HIV + naive and virologically suppressed patients. Regarding these aspects, the most recent data available for regimens containing dolutegravir and lamivudine (DTG / 3TC; DTG + 3TC) and dolutegravir and rilpivirine (DTG / RPV) will be investigated.
Moderatori: A. Di Biagio, S. Lo Caputo
| 11.10 - 11.15 | Introduction
A. Di Biagio, S. Lo Caputo |
| 11.15 - 11.35 | Evolving mindset with 2DR: the latest results to better identify the right patient at the right time
D. Ripamonti |
| 11.35 - 11.55 | Expanding experience with 2DR: the latest learnings from the real-life use of DTG/3TC in HIV+ naïve and switch patients
S. Di Giambenedetto |
| 11.55 - 12.10 | Discussion on Symposium issues |
Symposium
Pharmacology of antiviral drugs and vaccines
Symposium
Pharmacology of antiviral drugs and vaccines
At global level, the change in viral dynamics is severe enough to require a corresponding interest in discussing some of the issues directly related to the pandemic controls, i.e. the variability of the viruses and the microbiological aspects of vaccination. As far as the "pharmacology" issue is concerned, it is interesting noting that several antiretroviral drugs are substrates of enzymes belonging to the cytochrome P450 superfamily, which are polymorphically expressed, and consistent evidences are available in literature showing that genetic variation in these enzymes can predict the likelihood of anti-HIV treatment success, toxicity and/or the potential for drug-drug interactions. Preliminary evidences are also available showing that allelic variants of genes involved in the pharmacodynamics of antiretroviral drugs can impact on the clinical outcome of people living with HIV.
Chairs: G. Scarlatti, M. Zazzi
| 12.15 - 12.30 | Pharmacogenetics of drug response in antiviral therapies
J. Cusato |
| 12.30 - 12.45 | Variability and evolution of viruses: biological and clinical aspects
C.F. Perno |
| 12.45 - 13.00 | Vaccines against viruses: the microbiological point of view
I. Cassaniti |
| 13.00 - 13.15 | The influence of inflammation on antiviral drugs disposition and efficacy
G.C. Marchetti |
13.15 - 14.15 | Oral Poster
Foyer Auditorium - Oral Poster
Oral Poster
Antiretroviral Therapy I
Chairs: F. Bai, V. Colangeli
| 13.15 - 13.20 | OP 1 Real-life Experience with Dolutegravir-Based Two-Drug Regimens
|
| 13.22 - 13.27 | OP 2 Comparison of efficacy and tolerability of Dolutegravir / Rilpivirine or Dolutegravir / Lamivudine in experienced HIV-1 positive patients switched from a three-drug regimen based on Non-Nucleoside Reverse Transcriptase Inhibitors in a single center in Italy
|
| 13.29 - 13.34 | OP 3 Efficacy and safety of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically-suppressed HIV patients (EBONY Study)
|
| 13.36 - 13.41 | OP 4 Efficacy and tolerability of a switch to bictegravir/emtricitabine/tenofovir alafenamide in virally suppressed PLWH
|
| 13.43 - 13.48 | OP 5 Efficacy, safety and feasibility of a rapid antiretroviral therapy starting B/F/TAF in advanced hiv disease (Rainbow study)
|
| 13.50 - 13.55 | OP 6 Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV (PLWH) in routine clinical practice: 6-month results of the Italian BICSTaR cohort
|
Oral Poster
Comorbidities/Miscellaneous
Chairs: L. Calza, F. Carli
| 13.15 - 13.20 | OP 7 MARAND-X: clinical trial on the use of less neurotoxic antiretrovirals in HAND
|
| 13.22 - 13.27 | OP 8 Management of diabetes mellitus in people living with HIV and diabetes: a single-center experience
|
| 13.29 - 13.34 | OP 9 The interplay between resilience and health related quality of Life in PLWH during the COVID era: a comparison of a geriatric cohort with a cohort of PLWH younger than 65 years
|
| 13.36 - 13.41 | OP 10 Efficacy and Tolerability of Doravirine + Raltegravir combination regimen as therapy of switch in ART experienced PLWHIV: the DOR-INI experience
|
| 13.43 - 13.48 | OP 11 Trends of polypharmacy and 2DR antiretroviral use: a 15-year observational matched-cohort study
|
| 13.50 - 13.55 | OP 12 Rapid, drug-resistance-driven, start of antiretroviral therapy: an open-label, prospective, proof-of-concept, clinical study (TWODAY Study)
|
Oral Poster
HIV & COVID I
Chair: P. Maggi
| 13.15 - 13.20 | OP 13 UV irradiation and SARS‐CoV‐2: a focus on UVA/UVB/UVC -inactivation on viral replication
|
| 13.22 - 13.27 | OP 14 Determinants and characteristics of progressor and non progressor SARS COV-2 infected patients
|
| 13.29 - 13.34 | OP 15 Metabolic associated fatty liver disease is highly prevalent in the post-acute COVID syndrome
|
| 13.36 - 13.41 | OP 16 Assessment of well-being, resilience and intrinsic capacity in patients with post-acute COVID-19 syndrome
|
| 13.43 - 13.48 | OP 17 Achieving virological control in pan-resistant HIV-1 infection
|
| 13.50 - 13.55 | OP 18 Resilience and frailty in people living with HIV during the COVID era: two complementary constructs associated with health-related quality of life
|
Oral Poster
Coinfections and Hepatitis
Chairs: P. Colletti, I. Maida, G. Mazzola
| 13.15 - 13.20 | OP 19 Impact of polypharmacy and aging on the risk of multiple drug-drug interactions (DDIs) in HCV patients treated with pangenotypic direct-acting antivirals (pDAA)
|
| 13.22 - 13.27 | OP 20 HBeAg levels vary across the different phases of HBV infection, and can be predictive of therapeutic outcome in the setting of immunosuppression-driven HBV reactivation
|
| 13.29 - 13.34 | OP 21 HCV knowledge and awarness among injecting drug users in the direct acting antivirals era
|
| 13.36 - 13.41 | OP 22 A pilot intervention for HCV elimination among MSM in Rome: an update on more than 1200 screened individuals
|
| 13.43 - 13.48 | OP 23 Humoral response to mRNA SARS-CoV-2 vaccine in cirrhotic patients without prior exposure to the virus
|
| 13.50 - 13.55 | OP 24 Syphilis reinfection in people living with HIV (PLWH): a monocentric retrospective study
|
Oral Poster
Immunopathogenesis I
Chair: G. Liuzzi
| 13.15 - 13.20 | OP 25 Decreased neutralization of the B.1.525 (Nigerian) SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals
|
| 13.22 - 13.27 | OP 26 Severity of COVID-19 patients predicted by serum sphingolipids signature
|
| 13.29 - 13.34 | OP 27 Expansion of myeloid derived suppressor cells contribute to platelet activation by L-Arginine deprivation during SARS-CoV-2 infection
|
| 13.36 - 13.41 | OP 28 Cysteamine is an approved drug with antiviral and immunomodulatory properties promising for COVID-19 treatment
|
| 13.43 - 13.48 | OP 29 High CD169 monocyte/lymphocyte ratio reflects the immuno-phenotyping disruption and predicts oxygen need in COVID-19 patients
|
| 13.50 - 13.55 | OP 30 Effect of SARS-CoV-2 sequences on immune response in A549-ACE2 lung cells
|
Oral Poster
Epidemiology/Social Sciences I
Chair: A. Bianchi
| 13.15 - 13.20 | OP 31 SARS-CoV-2 evolutionary dynamics in the first phase of the epidemic in Italy
|
| 13.22 - 13.27 | OP 32 Characterization of SARS-CoV-2 variants circulating in Central Italy by deep-sequencing of full-length S gene
|
| 13.29 - 13.34 | OP 33 Impact of COVID pandemic and anti-SARS-CoV-2 immunization on vaccination against sexually transmitted infections
|
| 13.36 - 13.41 | OP 34 Influenza vaccine: knowledge and beliefs among adherent PLWH during the first seasonal campaign of the COVID-19 era
|
| 13.43 - 13.48 | OP 35 Results of a SARS-CoV-2 worker screening in the Marche Nord companies to prevent virus infection in the workplace
|
| 13.50 - 13.55 | OP 36 A mixed method of follow-up with total patient care provided continuum with saving of hospital checks during the COVID-19 pandemic
|
Oral Poster
Epidemiology/Social Sciences II
Chairs: M. Breveglieri, T.S. Prestileo
| 13.15 - 13.20 | OP 37 HIV-related internalized stigma and patient health engagement (PHE) model in an Italian cohort of people living with HIV
|
| 13.22 - 13.27 | OP 38 Talking about stigma and Hiv prevention, the artists' contribution
|
| 13.29 - 13.34 | OP 39 A visual scale to evaluate the quality of life in PLWHA. Fourth-90, utopia or reality?
|
| 13.36 - 13.41 | OP 40 Health-related quality of life (HRQoL) from HIV patients' perspective: comparison of patients-reported outcome (PRO) measures among people living with HIV (PLWH) and other chronic clinical conditions
|
| 13.43 - 13.48 | OP 41 Using technology to support vulnerable PLWHIV at the time of coronavirus
|
| 13.50 - 13.55 | OP 42 Impact of SARS-CoV-2 pandemic on quality of life in people with HIV
|
Sponsored Symposium
Continuous innovation for long-term treatment success
Con la sponsorizzazione di:
Sponsored Symposium
Continuous innovation for long-term treatment success
The advent of antiretroviral therapy (ART), once-daily single tablet regimens (STRs) combining efficacy and long-term safety in a simpler and simpler way, represents some of the most significant milestones that have helped bring radical change in the outlook for people living with HIV. However, there are still some clinical and virological needs in the achievement of the long-term treatment success. The Symposium is designed both to rethink the determinants of long-term treatment success and take a look to the present and future therapeutic options. It's a matter of quality or quantity?
Chair: S. Rusconi
| 14.15 - 14.20 | Introduction
S. Rusconi |
| 14.20 - 14.40 | Driving Innovation
F. Rogatto |
| 14.40 - 14.50 | Clinical and virological debate: what is meant by long-term treatment success from a virological point of view?
C.F. Perno |
| 14.50 - 15.00 | Clinical and virological debate: what is meant by long-term treatment success from a clinical point of view?
M. Andreoni |
| 15.00 - 15.10 | Today's choices for the long treatment success
S. Lo Caputo |
| 15.10 - 15.15 | Take-home messages
S. Rusconi |
Symposium
Behavioral and social impact of COVID-19 in PLWH
Symposium
Behavioral and social impact of COVID-19 in PLWH
COVID-19 has heavily impacted the lives of PLHIV for a number of different reasons, ranging from the difficulty in accessing infectious disease units and keeping in contact with their doctors, to changes in relational and behavioural habits - traumas to which people with HIV have been exposed in the past. Prolonged periods of lockdown, social distancing, forced isolation and being in the condition to transmit a virus to others again have evoked old fears. COVID-19 has also highlighted and increased health inequalities: vulnerable people have to struggle to take care of basic needs such as food and shelter, while little has been done to ensure equity and address the health and socioeconomic disparities of vulnerable communities. This symposium tries to shed some light on these different aspects.
Chairs: P. Meli, A. Saracino
| 15.20 - 15.25 | Introduction |
| 15.25 - 15.40 | Health inequalities in the COVID-19 era
V. Peragine |
| 15.40 - 15.55 | Mental health in the COVID era
A. Bove, A. Perziano |
| 15.55 - 16.10 | Role of digital technologies (telemedicine): pro and cons
F. Gabbrielli, F.v. Schloesser |
| 16.10 - 16.20 | Discussion on Symposium issues |
Symposium
SARS-CoV-2 infection in persons living with HIV
Symposium
SARS-CoV-2 infection in persons living with HIV
Despite several reports have been produced that investigate Covid-19 in HIV-infected patients, there is still no consensus whether HIV+ individuals do indeed display a most severe disease course as compared to HIV-uninfected peers. Likewise, given the HIV-driven immune dysfunction, not much is known about the immune response to Covid-19 vaccination in HIV+ patients. The most recent data describing Covid-19 clinical and immunological correlates in persons living with HIV (PLWH) will be presented within this Symposium, together with data describing the immunologic response to Covid-19 vaccination in this group of patients. Retention in care has long been considered a major goal in the best management of PLWH, that has been suggested to be potentially overhung by shifts in clinical efforts towards Covid-19 patients. The Symposium will approach the most recent findings describing retention in care in PLWH during Covid-19 pandemic as well as strategies to most efficaciously support it.
Chairs: A. Calcagno, A. De Rossi
| 16.25 - 16.30 | Introduction |
| 16.30 - 16.45 | Impact of HIV and comorbidities in COVID-19 clinical course
A.M. Geretti |
| 16.45 - 17.00 | HIV and SARS-CoV-2: two viruses challenging the immune system
C. Agrati |
| 17.00 - 17.15 | Retention in care during COVID-19 pandemic
E. Girardi, F. Schloesser |
| 17.15 - 17.25 | Discussion on Symposium issues |
Symposium
Novel long-acting therapies for the treatment of Multidrug-Resistant (MDR) HIV-1 infection: let's go undetectable again
Symposium
Novel long-acting therapies for the treatment of Multidrug-Resistant (MDR) HIV-1 infection: let's go undetectable again
The Symposium will focus on the new long-acting antiretrovirals designed to treat HIV+ persons harboring a virus resistant to other HIV treatments. Among others the symposium will share details on post attachment inhibitors through a unique mechanism of action blocks HIV-1 entry into cells, while preserving normal immune function. Effective against multiple drug-resistant strains, regardless of viral tropism, with high tolerability and safety, it represents a novel approach in the management of multi-drug-resistant (MDR) HIV infection.
Chair: M. Andreoni
| 17.30 - 17.35 | Introduction
M. Andreoni |
| 17.35 - 17.50 | New mechanism of action for durable viral suppression
C.F. Perno |
| 17.50 - 18.05 | The real world experience: lessons for clinical practice
A. Castagna |
| 18.05 - 18.20 | Long acting ARVs: the importance of pharmacokinetics, adherence and drug-drug interactions in a new era
G. Di Perri |
| 18.20 - 18.30 | Discussion on Symposium issues |
Oral Communications
Clinical HIV
Oral Communications
Clinical HIV
Chairs: M. Malena, C. Sagnelli
| 10.05 - 10.20 | Redesigning pregnancy in PLWH 2021
F. Vichi |
| 10.20 - 10.30 | OC 1 Coinfection with Hepatitis B Virus and/or Hepatitis C Virus is a risk factor for HIV virological rebound in course of antiretroviral therapy
|
| 10.32 - 10.42 | OC 2 Transitions in frailty phenotype states and its association with frailty index: A multi-state Markov model study
|
| 10.44 - 10.54 | OC 3 Intrapartum use of zidovudine in HIV pregnant women in Italy. Is it still being used in the era of U=U?
|
Oral Communications
Coinfections and Hepatitis
Oral Communications
Coinfections and Hepatitis
Chair: G. Taliani
| 11.10 - 11.25 | New anti-HBV drugs: virological and immunological bases
V. Svicher |
| 11.25 - 11.35 | OC 9 Enrichment of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg secretion and alters its structural stability
|
| 11.37 - 11.47 | OC 10 HBcrAg strongly correlates with higher HDV replicative activity and with enhanced liver inflammation and damage: implications for HBcrAg as a biomarker of disease progression in the setting of HDV co-infection
|
| 11.49 - 11.59 | OC 11 Endocrine pathways of non-alcoholic fatty liver disease in people living with HIV
|
Oral Communications
Clinical HIV & Clinical COVID I
Oral Communications
Clinical HIV & Clinical COVID I
Chairs: G. Lapadula, M.C. Moioli
| 12.15 - 12.30 | Therapeutic approaches with monoclonal antibodies in HIV and SARS-CoV-2 infections
A.M. Cattelan |
| 12.30 - 12.40 | OC 12 Higher risk of MAbs clinical failure associated to bamlanivimab/etesevimab exposure and to infection by SARS-CoV-2 P.1/Gamma variant of concern in a real life setting
|
| 12.42 - 12.52 | OC 13 Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection
|
| 12.54 - 13.04 | OC 14 Real life use of monoclonal antibodies and their impact on SARS-CoV-2 clearance kinetics: a single centre experience
|
Oral Communications
Epidemiology/Social sciences II
Oral Communications
Epidemiology/Social sciences II
Chairs: A. Cascio, A. Colucci
| 14.15 - 14.25 | OC 15 Correlates of treatment and disease burden in PLWH in Italy
|
| 14.27 - 14.37 | OC 16 The fourth “95” is at reach
|
| 14.39 - 14.49 | OC 17 Narratives of HIV-positive patients in the DIAMANTE study
|
| 14.51 - 15.01 | OC 18 A telephone-based multidimensional interview in elderly people living with HIV from the GEPPO cohort
|
Expert Meeting
Monoclonal antibodies and their role in COVID-19 patients: results and perspectives
Expert Meeting
Monoclonal antibodies and their role in COVID-19 patients: results and perspectives
The development of therapeutic monoclonal antibodies is currently at the front line of fighting against the COVID-19 pandemic. However, the emergence and proliferation of SARS-CoV-2 variants conferring resistance to some antibodies is deeply concerning. Furthermore, as additional variants of concern will likely continue to emerge, there is a high unmet medical need for therapeutics that, alone or in combination, can remain effective as the virus evolves. The Expert Meeting will present the state of the art of virological research against COVID-19 with a look at the promising clinical data emerging from the use of monoclonal antibodies and the most recent clinical experiences in the field.
Chair: M.S. Clerici
| 15.20 - 15.25 | Introduction |
| 15.25 - 15.35 | From viral pathophysiology to symptoms: rational, candidates, results of early treatment of COVID - 19
G. Di Perri |
| 15.35 - 15.45 | Emerging SARS-CoV-2 variants and their impact in pandemics therapy
C.F. Perno |
| 15.45 - 15.55 | Fighting COVID-19 with neutralizing monoclonal antibodies: the importance of high barrier to resistance
A. Antinori |
| 15.55 - 16.05 | The journey of COVID-19 patients: experiences of clinical practice
S. Lo Caputo |
| 16.05 - 16.20 | Discussion |
Expert Meeting
Vaccines roadmap: the humanity game-changer
Sponsorizzato da: 
Expert Meeting
Vaccines roadmap: the humanity game-changer
History is characterized by epidemic and pandemic, documented since the second century with the Antonine plague, caused by unknown pathogenic that over the years we have been able to better know and manage. The crucial course that revolutionized the humanity history saving billion of lives from certain death began with the smallpox vaccine. The scientific progress made possible the eradication of some infections that nowadays belong to the past. The aim of the Expert Meeting is to deepen the knowledge on epidemiologic and clinical data, looking at how the vaccines can still make the difference in managing the HIV and SARS-COV 2 pandemics.
Chair: A.M. Cattelan
| 16.25 - 16.30 | Introduction
A.M. Cattelan |
| 16.30 - 16.45 | Epi-pills: deep dive on vaccine studies
B. Simone |
| 16.45 - 17.00 | HIV Vaccine: a long path
A. Castagna |
| 17.00 - 17.15 | COVID-19 Vaccine: dynamic journey
P. Bonanni |
| 17.15 - 17.25 | Questions & Answers |
Symposium
Co-infections in 2021
Symposium
Co-infections in 2021
Chairs: M. Puoti, L. Sarmati
| 17.30 - 17.35 | Introduction |
| 17.35 - 17.50 | 40 years of opportunistic infections
M. Lichtner |
| 17.50 - 18.05 | The challenges related to the upcoming HDV drugs
S. Schivazappa |
| 18.05 - 18.20 | New perspectives in non-tuberculous mycobacteria in HIV and non-HIV patients: focus on new therapeutic approaches
R. Parrella |
| 18.20 - 18.30 | Discussion on Symposium issues |
Oral Communications
Epidemiology/Social sciences I
Oral Communications
Epidemiology/Social sciences I
Chair: L. Sighinolfi
| 10.05 - 10.15 | OC 4 Long-term follow-up in a community-based PrEP cohort: controlled increase in risk exposure
|
| 10.17 - 10.27 | OC 5 Chemsex use in a HIV pre-exposure prophylaxis (PrEP) program based in Milan
|
| 10.29 - 10.39 | OC 6 Between loss to follow-up and persistence of risky sexual behaviors: how the COVID-19 pandemic impacted access to PrEP
|
| 10.41 - 10.51 | OC 7 Impact of COVID pandemic on sexual habits and pre-exposure prophylaxis retention in care in a community-based service
|
| 10.53 - 11.03 | OC 8 School-based sexuality education in Italy 2016-2020: a highly heterogeneous scenario
|
Expert Meeting
MDR pathogens in the COVID-19 era: experiences with Cefiderocol
Con la sponsorizzazione non condizionante di: 
Expert Meeting
MDR pathogens in the COVID-19 era: experiences with Cefiderocol
Antimicrobial resistance (AMR) is a growing global problem to which the ongoing COVID-19 pandemic may further contribute. Every year, drug-resistant microbes are responsible for an estimated 700,000 deaths and future projections for the impact of unresolved AMR are as high as 10 million deaths per year by 2050. One of the most significant threats in global health is the carbapenem-resistant gram-negative bacteria and lack of efficient antibiotics. The World Health Organization designated carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii as high-priority pathogens, which urgently need new antimicrobial development. The Expert Meeting aims to provide information on real life cases treated with Cefiderocol, a recent new option for patients with multidrug-resistant Gram-negative bacterial infections.
Chair: P. Viale
| 11.10 - 11.25 | From in vitro activity to clinical efficacy
P. Viale |
| 11.25 - 11.35 | Real-life experiences with Cefiderocol in Pseudomonas infections
M. Meschiari |
| 11.35 - 11.45 | Real-life experiences with Cefiderocol in Acinetobacter baumannii infections
G. Tiseo |
| 11.45 - 11.55 | Cefiderocol place in therapy
M. Giannella |
| 11.55 - 12.05 | Questions & Answers |
| 12.05 - 12.10 | Take-home messages
P. Viale |
Expert Meeting
The first of a new generation NNRTI: the opportunity to get to the heart of PLWH
Con la sponsorizzazione non condizionante di:
Expert Meeting
The first of a new generation NNRTI: the opportunity to get to the heart of PLWH
PLWH may be predisposed to higher risk of Cardiometabolic Disorders such as dyslipidemia, cardiovascular disease and diabetes. In fact, metabolic syndrome affects up to 52% of PLWH. EACS guidelines suggest an ARV modification in case of CVD risk. Here, we review the efficacy and safety profile of the new generation of NNRTI, with a focus on Cardiometabolic Disorders.
Moderatore: M. Andreoni
| 12.15 - 12.20 | Introduction
M. Andreoni |
| 12.20 - 12.35 | The first of a new generation NNRTI: the opportunity to get to the heart of PLWH
A. Antinori |
| 12.35 - 13.05 | Discussion |
| 13.05 - 13.15 | Take-home messages and conclusions
M. Andreoni |
Expert Meeting
Hyperinflammation and COVID-19: from research to clinical practice
Expert Meeting
Hyperinflammation and COVID-19: from research to clinical practice
The natural history of COVID-19 includes an initial stage of viral replication that can be followed by a second stage of immunopathology driven by a hyperinflammatory response to SARS-CoV-2 infection. This is characterized by excessive release of pro-inflammatory cytokines (i.e. IL-1, IL-6, IL-8, TNF, GM-CSF, and IFN-g). This increasing evidence has prompted the investigation of immunomodulatory therapies in order to 1) attenuate the exaggerated immune response of the host; 2) identify the most appropriate immunomodulating strategies; 3) the optimal timing of such interventions, and achieve the more robust clinical benefits in patients with COVID-19.
Chairs: A. Cossarizza, A. Gori
| 14.15 - 14.20 | Introduction |
| 14.20 - 14.35 | COVID-19 and IL-1, targeting the inflammatory cascade
G. Cavalli |
| 14.35 - 14.50 | Tracing the pathway to the SAVE-MORE study results
E. Nicastri |
| 14.50 - 15.05 | On the way to real-world experiences
A. Bandera |
| 15.05 - 15.15 | Discussion |
Expert Meeting
Roundtable New treatment options for heavily pretreated patients
Con la sponsorizzazione non condizionante di:
Expert Meeting
Roundtable New treatment options for heavily pretreated patients
Patients with multidrug-resistant HIV currently make up a smaller but still challenging part of the population living with HIV. Challenges with tolerability, safety, and drug-to-drug interactions may further decrease the number of acceptable antiretroviral therapies available to design effective treatment regimens. There remains an unmet need for these individuals who are considered heavily treatment-experienced (HTE) and who are unable to successfully suppress their HIV. Until the past couple of years, there were a limited number of targets on the human immunodeficiency virus that could be hit by available medications. Recently, several new targets have emerged: the Experts will review the clinical data obtained with the different strategies pursued in this clinical setting.
Discussants: A. Castagna, F. Maggiolo, G.C. Marchetti, C. Mussini
Oral Communications
Antiretroviral Therapy I
Oral Communications
Antiretroviral Therapy I
Chair: E.M. Erne
| 16.25 - 16.35 | OC 19 Trajectories of CD4/CD8 ratio at 96 weeks after switch to dolutegravir-based dual therapies in a multicentre cohort of ART-experienced patients
|
| 16.37 - 16.47 | OC 20 Increasing Trend of Pretreatment Integrase Inhibitors Resistance in a Cohort of Antiretroviral Therapy-Naïve People Living with HIV
|
| 16.49 - 16.59 | OC 21 Role of genotypic testing results for predicting virological failure in persons living with HIV with HIV-RNA ≤50 copies/mL who require an ART switch
|
| 17.01 - 17.11 | OC 22 Evaluation of virological response and resistance profile in virologically suppressed HIV-1 infected individuals switching to a bictegravir based regimen in a real-life setting
|
| 17.13 - 17.23 | OC 23 Evaluation of total HIV-DNA and residual viremia in HIV-1 infected individuals enrolled on the Be-OnE study who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: results over 96 weeks
|
Oral Communications
Clinical HIV & Clinical COVID II
Oral Communications
Clinical HIV & Clinical COVID II
Chairs: N. Petrosillo, S. Piconi
| 17.30 - 17.40 | OC 27 Impact of home treatment with glucocorticoids on risk of in-hospital death in patients with COVID-19 pneumonia
|
| 17.42 - 17.52 | OC 28 Treatment of COVID-19 severe pneumonia: do all patients benefit from adding tocilizumab to glucocorticoids? An open label non-randomized study
|
| 17.54 - 18.04 | OC 29 SARS-CoV-2 viral decay in COVID-19 patients treated with monoclonal antibodies in relationship to viral variant
|
| 18.06 - 18.16 | OC 30 Effectiveness of COVID-19 vaccine in health care workers, Milan, Italy
|
| 18.18 - 18.28 | OC 31 Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH
|
Round Table
40 years of HIV: reforming law 135/90 to achieve 2030 SDG and AIDS elimination
Meet the Community
40 years of HIV: reforming law 135/90 to achieve 2030 SDG and AIDS elimination
Chairs: G.V. Calvino, L.A.R. Rancilio
Expert Meeting
ICONA-PROs in the real-life setting
Con la sponsorizzazione non condizionante di:
Expert Meeting
ICONA-PROs in the real-life setting
As infection with the Human Immunodeficiency Virus (HIV) has evolved into a chronic disease there is a strong rationale for evaluating the impact of antiretroviral therapies on broader aspects of patient's lives, including psychological, symptoms, functioning, well-being, satisfaction, etc. and the impact on the patient. Therefore, perceived health-related quality of life (HRQoL) became a prominent and important patient-reported outcomes (PROs) measure in HIV care, defined as any report of the status that comes directly from the patient without interpretation by a clinician or anyone else. This is particularly true in a cohort setting such as ICONA which decided to launch a new project devoted to HRQoL and PROs including the QoL APP, created to better respond to requests of effective digital tool to collect measures of patient- reported outcomes.
Chairs: A. Cingolani, A. d'Arminio Monforte
| 13.15 - 13.20 | Introduction
A. Cingolani, A. d'Arminio Monforte |
| 13.20 - 13.30 | The ICONA QoL Project: rationale, objectives
A. d'Arminio Monforte |
| 13.30 - 13.40 | Measure the HIV Quality of Life through patient-reported outcomes (PROs)
A. Cingolani |
| 13.40 - 14.00 | Digital technologies to support the patient: the new ICONA QoL APP
I. Fanti, A. Tavelli |
| 14.00 - 14.15 | Questions & Answers |
Oral Communications
Epidemiology/Social sciences III
Oral Communications
Epidemiology/Social sciences III
Chairs: B.M. Celesia, B. Suligoi
| 16.25 - 16.40 | Breastfeeding: the ultimate U=U's goal?
M.G. Di Benedetto |
| 16.40 - 16.50 | OC 24 From u = u to breastfeeding of women with virosuppressed HIV
|
| 16.52 - 17.02 | OC 25 Preferences in long acting agents for HIV treatment in women living with HIV: a cross-sectional evaluation among 6 Italian clinical centers
|
| 17.04 - 17.14 | OC 26 HCV infection among women prisoners: a snapshot of the italian ROSE network
|
09:00 - 10:00
Keynote Lectures
10:05 - 11:05 | Symposium
Approaching the Long Acting Therapy in HIV
11:10 - 12:10 | Symposium
Rethinking antiretroviral therapy: new issues, new approaches
12:15 - 13:15 | Satellite Symposium
How the past shapes the future
12:15 - 13:15 | Satellite Symposium
How the past shapes the future
13.15 - 14.15 | Oral Poster
Foyer Auditorium - Oral Poster
14:00 - 14:45 | Symposium
The Italian Fast-Track Cities network
14:50 - 15:50 | Symposium
Long-COVID and HIV: which signatures?
16:20 - 16:40
SIMIT & ICAR-CROI Awards - Closing remarks
10:05 - 11:05 | Oral Communications
Clinical HIV & Clinical COVID III
11:10 - 12:10 | Oral Communications
Immunopathogenesis I
12:15 - 13:15 | Oral Communications
Comorbidities I
14:15 - 14:45 | Oral Communications
Antiretroviral Therapy II
14:50 - 16:20 | Oral Communications
Antiretroviral Therapy III
10:05 - 11:05 | Expert Meeting
Hepatitis D virus in 2021: new challenges in tough-to-treat patients
11:10 - 12:10 | Expert Meeting
Remdesivir from the pivotal trials to the real world experiences: are there other open questions?
12:15 - 13:15 | Oral Communications
Immunopathogenesis II
14:15 - 14:45 | Oral Communications
Comorbidities II
14:50 - 16:20 | Oral Communications
Virology and Pharmacology II
10:05 - 11:05 | Special Session
Riunione operativa Fast-Track
11:10 - 12:10 | Meet the Community
Sex Check for Prep
14:15 - 14:45 | Oral Communications
Virology and Pharmacology I
14:50 - 16:20 | Oral Communications
Epidemiology/Social sciences IV
Keynote Lectures
Keynote Lectures
Chairs: P. Bagnarelli, F. Castelli
| 09.00 - 09.30 | Antiretroviral therapy: future is coming
A. Castagna |
| 09.30 - 10.00 | From HIV to SARS-CoV-2: how pandemics affected the integration between laboratory and clinics
M.R. Capobianchi |
Symposium
Approaching the Long Acting Therapy in HIV
Symposium
Approaching the Long Acting Therapy in HIV
Long Acting (LA) therapies offer a key difference to currently available ART regimens: patient choice related to their preferred way to administer medications. The affected community and HIV providers are very interested in exploring the role of long-acting therapies to address some types of barriers to medication adherence. This Symposium will address the rationale and the current data supporting the efficacy and safety of the first complete LA ART regimen, cabotegravir and rilpivirine, and outline associated opportunities and challenges with the implementation of long-acting therapy for the treatment and prevention of HIV.
Chairs: A. Antinori, G. Rizzardini
| 10.05 - 10.10 | Introduction
A. Antinori, G. Rizzardini |
| 10.10 - 10.30 | Evidence of clinical data and impact in PLWH
S. Nozza |
| 10.30 - 10.50 | What's behind Long Acting
S. Bonora |
| 10.50 - 11.05 | Discussion on Symposium issues |
Symposium
Rethinking antiretroviral therapy: new issues, new approaches
Symposium
Rethinking antiretroviral therapy: new issues, new approaches
Great strides have been made in HIV prevention and treatment. Life expectancy of people living with Hiv infection, appropriately treated is now almost the same as the general population, a huge success that needs to be maintained and translated into a good quality of life. The range of available antiretroviral therapies has expanded considerably over the years to now include several classes of antiretrovirals. New drugs with unique mechanisms of action likely effective also against HIV strains with resistance will be available very soon and long-acting therapies that could be taken once every month, once every two months or even less will be available in the next years.This Symposium will debate the most critical points for a proper management of HIV prevention and treatment in this dynamic scenario.
Chairs: G.M. Corbelli, M.E. Quiros Roldan
| 11.10 - 11.25 | Prevention
S. Nozza |
| 11.25 - 11.40 | Naive
V. Spagnuolo |
| 11.40 - 11.55 | Switch
L. Taramasso |
| 11.55 - 12.10 | Failure
R. Gagliardini |
Satellite Symposium
How the past shapes the future
Con la sponsorizzazione non condizionante di:
Satellite Symposium
How the past shapes the future
In this changing scenario caring for HIV is constantly a challenge and with it both the management of long-term antiretroviral therapy and the unmet needs of every single HIV-positive patient and at-risk population. PLWH require long-life treatments while maintaining durability and tolerability of antiretroviral regimen. The aim of symposium is going through the long innovation path focusing on value of ART history in the new global landscape depicted by COVID-19 pandemic. Furthermore, data obtained from experience will be discussed to better support treatment strategies in daily practice for improving patients care.
Chair: C. Mussini
Satellite Symposium
How the past shapes the future
Con la sponsorizzazione non condizionante di:
Satellite Symposium
How the past shapes the future
In this changing scenario caring for HIV is constantly a challenge and with it both the management of long-term antiretroviral therapy and the unmet needs of every single HIV-positive patient and at-risk population. PLWH require long-life treatments while maintaining durability and tolerability of antiretroviral regimen. The aim of symposium is going through the long innovation path focusing on value of ART history in the new global landscape depicted by COVID-19 pandemic. Furthermore, data obtained from experience will be discussed to better support treatment strategies in daily practice for improving patients care.
Chair: C. Mussini
13.15 - 14.15 | Oral Poster
Foyer Auditorium - Oral Poster
Oral Poster
Antiretroviral Therapy II
Chair: A. Londero
| 13.15 - 13.20 | OP 43 Changes in serum inflammatory and immune activation markers associated with lamivudine/dolutegravir and tenofovir alafenamide/emtricitabine/bictegravir as initial antiretroviral treatment
|
| 13.22 - 13.27 | OP 44 Cardiovascular risk and lipid profile after switching to TAF/FTC/RPV or TAF/FTC/EVG/cobi in people living with HIV and controlled plasma viremia
|
| 13.29 - 13.34 | OP 45 Who could be eligible for long-acting antiretroviral treatment? A snapchat from Antiviral Response Cohort Analysis (ARCA) Italian cohort
|
| 13.36 - 13.41 | OP 46 HIV-DNA decay in ART-naïve patients starting dolutegravir plus lamivudine vs triple therapy
|
| 13.43 - 13.48 | OP 47 Real-life impact of drug toxicity on dolutegravir tolerability: clinical practice data from a multicenter Italian cohort
|
| 13.50 - 13.55 | OP 48 Prevalence and incidence of multidrug resistance in the ARCA database, 2020 update
|
Oral Poster
HIV & COVID II
Chair: M.A. Di Pietro
| 13.15 - 13.20 | OP 49 Real life use of the anti-SARS CoV-2 monoclonal antibodies in the early phase of infection: planning, enrollment, administration and monitoring
|
| 13.22 - 13.27 | OP 50 Learning by doing: effects of monoclonal antibody treatment on the outcome of ambulatory patients with COVID-19
|
| 13.29 - 13.34 | OP 51 Efficacy, safety and virological clearance in course of treatment with anti-SARS-CoV-2 monoclonal antibodies in patients diagnosed with mild-moderate COVID-19
|
| 13.36 - 13.41 | OP 52 Ex vivo efficacy of currently licensed anti-SARS-CoV-2 monoclonal antibodies
|
| 13.43 - 13.48 | OP 53 Real-life use of remdesivir-containing regimens in Coronavirus Disease-2019: a retrospective case-control study
|
| 13.50 - 13.55 | OP 54 SARS-CoV-2 infection Among Persons living with HIV
|
Oral Poster
Immunopathogenesis II
Chair: L. Sasset
| 13.15 - 13.20 | OP 55 Increased rates of indeterminate QuantiFERON-TB Gold Plus assay in severe COVID-19 patients reflect an impaired interferon-gamma secretion and correlate with the profound reduction of T-lymphocyte subsets in peripheral blood
|
| 13.22 - 13.27 | OP 56 Role of serum E-selectin as a biomarker of infection severity in Coronavirus Disease-19
|
| 13.29 - 13.34 | OP 57 Effects of viremia and CD4 recovery on the gut “microbiome-immunity” axis in naïve HIV-1 patients undergoing ART therapy
|
| 13.36 - 13.41 | OP 58 Cytokine profile of COVID-19 patients with and without active tuberculosis
|
| 13.43 - 13.48 | OP 59 Role of Tocilizumab in down regulating the concentration of sCD163 in a cohort of SARS-COV 2 infected patients with varying severity
|
| 13.50 - 13.55 | OP 60 Clinical and immunological characterization of SARS-CoV-2 infection in children
|
Oral Poster
Immunopathogenesis III
Chair: M. Massari
| 13.15 - 13.20 | OP 61 Binding and neutralizing antibodies to interferon (IFN) α/β and defective IFN transcriptional profile in COVID-19 patients
|
| 13.22 - 13.27 | OP 62 Plasma cytokine landscape reveals the importance of different molecular pathways in predicting COVID-19 severity and survival
|
| 13.29 - 13.34 | OP 63 Pregnant women develop a specific immunological long-lived memory against SARS-CoV-2
|
| 13.36 - 13.41 | OP 64 Role of Type-I and -II interferons in SARS-CoV-2 infection: convergent effect, different mechanisms
|
| 13.43 - 13.48 | OP 65 Persistence of humoral immune response after one year from COVID-19 diagnosis: evidence from a monocentric study
|
| 13.50 - 13.55 | OP 66 Immunogenicity and safety of two doses of BNT162b2 vaccine in very elderly subjects
|
Oral Poster
Social Sciences/Miscellaneous
Chairs: A. Franco, G. Madeddu
| 13.15 - 13.20 | OP 67 Patient outreach strategy to enhance retention to care of HIV-positive adolescent and youths: experience from HIV high burden setting
|
| 13.22 - 13.27 | OP 68 Knowledge of HIV and STIs: which are the most vulnerable populations? Results from a web-based survey in Italy
|
| 13.29 - 13.34 | OP 69 HIV and Adolescents. Evaluation of an HIV and STI prevention project for high school students
|
| 13.36 - 13.41 | OP 70 SARS-CoV-2 variants surveillace highlights local emergence of different genotypes
|
| 13.43 - 13.48 | OP 71 Access to HIV testing before and after SARS-CoV-2 pandemic in Milan: comparison between a health-care setting and a community setting
|
| 13.50 - 13.55 | OP 72 Characterization of PLWH with low-level viremia: results from the Italian ARCA cohort
|
Oral Poster
Epidemiology/Social Sciences III
Chairs: M. Farinella, V. Giacomet, C. Iaria
| 13.15 - 13.20 | OP 73 Pre-Exposure Prophylaxis (PrEP) though the SARS-CoV-2 pandemic period: the experience of the dedicated service of Tuscany Region in S.M.Annunziata Hospital, Florence
|
| 13.22 - 13.27 | OP 74 PreP experience at Milano Checkpoint: promoting health and well-being through the integration of complementary skills
|
| 13.29 - 13.34 | OP 75 Rapid tests in the pandemic: the "continuum of care" of Villa Maraini during the Covid-19 emergency
|
| 13.36 - 13.41 | OP 76 Covid-19 in HIV/AIDS out-of-hospital facilities in Lombardy
|
| 13.43 - 13.48 | OP 77 The COVID-19 pandemic impact on retention in care and viral suppression at the Infectious Diseases Unit of S. M. Annunziata Hospital, Florence: comparing 2019 and 2020 data
|
| 13.50 - 13.55 | OP 78 Reaching 90-90-90 in the municipality of Kilamba Kiaxi, Luanda, Angola. The experience of PIPSA project
|
Oral Poster
Virology
Chairs: V. Cento, B. Rossetti
| 13.15 - 13.20 | OP 79 Molecular evidence of HIV-1 transmission in a criminal case in Italy
|
| 13.22 - 13.27 | OP 80 Assessment of specific immunological response after administration of anti-meningococcal quadrivalent conjugate vaccine MENVEO® in a population with vertically-transmitted HIV infection
|
| 13.29 - 13.34 | OP 81 Regulation of m6A methylation as new therapeutic option against COVID-19
|
| 13.36 - 13.41 | OP 82 Characterization of humoral and cellular immune response after SARS-CoV-2 mRNA vaccine in HIV-1 infected patients
|
| 13.43 - 13.48 | OP 83 Safety and tolerability of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine in a diverse cohort of people with HIV (PWH)
|
| 13.50 - 13.55 | OP 84 Differences in response to mRNA BNT162b2 vaccine among a cohort of Health Care Workers (HCWs): insights into the potential of a booster dose
|
Symposium
The Italian Fast-Track Cities network
Con la sponsorizzazione non condizionante di:
Symposium
The Italian Fast-Track Cities network
The Fast-Track Cities initiative is a global partnership between cities and municipalities around the word and four core partners: the International Association of Providers of AIDS-Care (IAPAC), the Joint United Nations Programme on HIV/AIDS (UNAIDS), the United Nations Human Settlements Programme (UN-Habitat) and the City of Paris. Launched on Word AIDS Day 2012, the Network has grown to include more than 300 Cities and municipalities that are committed to attain the UNAIDS 95-95-95 targets by 2030. The aim of the Symposium is to discuss the global initiatives and to focus on the Italian Fast-Track Cities state of the art, in a round table involving the different Italian Fast-Track Cities' stakeholders.
Chair: A. d'Arminio Monforte
Moderatori: M. Cernuschi, F. Maggiolo
| 14.00 - 14.05 | Introduction
A. d'Arminio Monforte |
| 14.05 - 14.15 | The Global Network and ICAR-IAPAC partnership
B. Audoin |
| 14.15 - 14.40 | Round Table The Italian Fast-Track Cities network: common actions |
| 14.40 - 14.45 | Final considerations
B. Audoin, A. d'Arminio Monforte |
Symposium
Long-COVID and HIV: which signatures?
Symposium
Long-COVID and HIV: which signatures?
COVID-19 has the potential to affect people living with HIV (PLWH) in various ways, including be increased risk of COVID-19 acquisition and interruptions of HIV treatment and care. The purpose of this session is to evaluate the impact of COVID-19 among PLWH. In particular to explore how different processes involving aging, inflammation, and cardiovascular risk may interact in HIV and SARS-CoV-2 co-infection, particularly the long-term effects generated by the collision of the two pandemics.
Chairs: G. Guaraldi, E. Vicenzi
| 14.50 - 15.05 | Geroscience in long-COVID and HIV
N. Barzilai |
| 15.05 - 15.20 | Inflammaging in HIV & in long-Covid
M. Montano |
| 15.20 - 15.30 | Discussion |
| 15.30 - 15.40 | Fat matters in HIV and COVID-19
G. Besutti |
| 15.40 - 15.50 | Physical activity as pleasure and medicine
P.M. Cinque |
Sessione
SIMIT & ICAR-CROI Awards - Closing remarks
SIMIT & ICAR-CROI Awards - Closing remarks
Chairs: G.V. Calvino, M.R. Capobianchi, A.M. Cattelan, A. d'Arminio Monforte, C.M. Mastroianni, C. Mussini, G. Silvestri, M. Tavio, S. Vella
Oral Communications
Clinical HIV & Clinical COVID III
Oral Communications
Clinical HIV & Clinical COVID III
Chairs: P.A. Grossi, E. Vaccher
| 10.05 - 10.15 | OC 32 T-Lymphocyte subset absolute counts assessed at baseline represent a useful tool to predict 30-days mortality in hospitalized SARS-CoV-2 infected patients
|
| 10.17 - 10.27 | OC 33 HIV and SARS-CoV-2 co-infection: protective role of IL-10 in HIV-positive young individuals
|
| 10.29 - 10.39 | OC 34 Sequelae at 12 months after COVID-19 in hospitalized adults: a multicenter study
|
| 10.41 - 10.51 | OC 35 Bloodstream infections in COVID-19 patients: first-wave versus second-wave comparison
|
| 10.53 - 11.03 | OC 36 Impact of a pro-active Infectious Diseases Consultation for the Management of a Multidrug-resistant Organisms Outbreak in a COVID-19 Hospital: a Three-Months Quasi-Experimental Prospective Study
|
Oral Communications
Immunopathogenesis I
Oral Communications
Immunopathogenesis I
Chairs: G. d'Ettorre, G. Nunnari
| 11.10 - 11.25 | The age-dependent B-cell response to SARS-CoV-2 between innate and adaptive memory
R. Carsetti |
| 11.25 - 11.40 | Pregnancy and Sars-Cov-2: a novel virus in a unique population
M. Biasin |
| 11.40 - 11.50 | OC 37 SARS-CoV-2 plasmatic viremia and T-cell immune response in hospitalized COVID-19 patients
|
| 11.52 - 12.02 | OC 38 T-lymphocyte specific response to SARS-CoV-2 peptides is detectable in patients with multiple sclerosis under treatment with disease modifying therapies, despite absent or low-level anti-Spike antibody titers. Which are the possible clinical implications?
|
Oral Communications
Comorbidities I
Oral Communications
Comorbidities I
Chairs: P. Nasta, G. Parruti
| 12.15 - 12.30 | Into the lung: is there a synergy between HIV and SARS-CoV2?
A. Di Biagio |
| 12.30 - 12.40 | OC 39 SARS-CoV-2 infection and COVID-19 disease in a large cohort of PLWHIV
|
| 12.42 - 12.52 | OC 40 Meningococcus B Vaccination Effectiveness against Neisseria gonorrhoeae Infection in PLWH: a Case-control Study
|
| 12.54 - 13.04 | OC 41 A Machine Learning-Based Model to Predict the 15-Year Risk for Cardiovascular Disease in a Cohort of People Living with HIV
|
Oral Communications
Antiretroviral Therapy II
Oral Communications
Antiretroviral Therapy II
Chairs: A.M. Cattelan, N. Gianotti
| 14.15 - 14.25 | OC 47 Associations between weight changes and plasmatic pro-inflammatory cytokines in PLWH following ART initiation: data from the ICONA cohort
|
| 14.27 - 14.37 | OC 48 Weight gain after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in patient with stable viral suppression
|
Oral Communications
Antiretroviral Therapy III
Oral Communications
Antiretroviral Therapy III
Chairs: S. Cicalini, C. Torti
| 14.50 - 15.00 | OC 53 Effectiveness of lamivudine + dolutegravir (3TC+DTG) in persons living with HIV (PLWH) starting their first antiretroviral treatment
|
| 15.02 - 15.12 | OC 54 Reasons for choosing a TAF-based 3DR instead of a DTG-based 2DR as ART switch strategy for virologically suppressed PLWH in Italy
|
| 15.14 - 15.24 | OC 55 An Italian non-interventional retrospective and prospective study in HIV-positive adult outpatients treated with D/C/F/TAF: the DIAMANTE study
|
| 15.26 - 15.36 | OC 56 Prevalence, characteristics and outcome of Heavily treated experienced (HTE) HIV-infected patients: data from the Italian ICONA Cohort
|
| 15.38 - 15.48 | OC 57 BIC/FTC/TAF is effective on PLWH with low CD4 counts: real-life data from the Icona cohort
|
| 15.50 - 16.00 | OC 58 ART switch for pro-active, re-active or cost-saving reasons: a real world evaluation of the determinants over the period 2017-2020 in the Veneto Region
|
| 16.02 - 16.12 | OC 59 Switching to Emtricitabile/Tenofovir Alafenamide/Bictegravir on metabolic and hepatic safety: preliminary data from Surveillance Cohort Long-term Toxicity Antiretrovirals/antivirals (SCOLTA) project
|
Expert Meeting
Hepatitis D virus in 2021: new challenges in tough-to-treat patients
Expert Meeting
Hepatitis D virus in 2021: new challenges in tough-to-treat patients
Hepatitis delta virus (HDV), first discovered in Italy in 1977, is a small defective RNA virus which requires the helper function of HBV for its replication and transmission to anti-HDV-negative individuals. HDV infection can be transmitted either simultaneously with HBV infection (co-infection) or to people who are already chronic HBV carriers (super-infection). It has been estimated that 15-20 million people worldwide have a chronic HDV infection; in Italy prevalence is estimated around 7-8% among HBV infected people. Coinfections lead to more serious liver disease than hepatitis B infection alone. They are associated with faster progression to liver fibrosis, increased risk of liver cancer, and early decompensated cirrhosis and liver failure. Up to 90% of superinfected individuals will develop chronic infections of both hepatitis B and delta, of which approximately 70% will progress to cirrhosis (liver scarring), compared to 15-30% of those infected only with the hepatitis B virus. Until now, people with HDV had very limited treatment options and poor diagnosis. The Expert Meeting will focus on a new agent - bulevirtide - a first-in-class HBV and HDV entry inhibitor that targets the human NTCP (sodium taurocholate cotransporting polypeptide) transmembrane protein.
Chair: N. Coppola
| 10.05 - 10.10 | Introduction
N. Coppola |
| 10.10 - 10.30 | Current challenges in Hepatitis D: epidemiology, diagnosis and management 44 years after discovery
M.R. Brunetto |
| 10.30 - 10.50 | A new option for the treatment of chronic hepatitis delta: scientific evidence of the first-in-class entry inhibitor Bulevirtide
P. Lampertico |
| 10.50 - 11.00 | Discussion |
| 11.00 - 11.05 | Take-home messages and conclusions
N. Coppola |
Expert Meeting
Remdesivir from the pivotal trials to the real world experiences: are there other open questions?
Con la sponsorizzazione di:
Expert Meeting
Remdesivir from the pivotal trials to the real world experiences: are there other open questions?
The use of remdesivir, the first and only antiviral drug authorized in Europe for the treatment of COVID-19, is increasingly supported by numerous real-world data, which confirm the results of three randomized and controlled clinical trials, including the ACTT-1 study, the gold standard randomized, double-blind, placebo-controlled clinical trial on the efficacy of remdesivir. While in these studies no benefit on mortality rates or a non-statistically significant trend towards benefit for mortality were reported, the results of recent international real-world retrospective analyses on large data sets complete the picture provided by the randomized and controlled clinical trials, showing that hospitalised COVID-19 patients treated with remdesivir had a statistically significant reduction in mortality and improved survival compared to matched controls. These robust findings have been observed not only in the overall population but also across all subgroups of patients requiring supplemental oxygen.The meeting will be an opportunity to present a scientific update on the efficacy data and to share opinions and experiences about a year after the introduction of remdesivir in clinical practice in Italy.The Expert Meeting will be carried out through an interactive discussion between young and experienced infectious disease specialists, who will talk about their experience on the use of remdesivir in clinical practice.
Moderatore: S. Rusconi
Discussants: F.G. De Rosa, M. Falcone, T.A. Santantonio, F.S. Serino
| 11.10 - 11.15 | COVID-19: Remdesivir from the pivotal trials to the real-world experience
S. Rusconi |
| 11.15 - 11.30 | Remdesivir from the clinical trials to the real Practice: the open questions
T.A. Santantonio |
| 11.30 - 11.45 | Evidence from the real-world analyses: the initial answers
F.G. De Rosa |
| 11.45 - 12.05 | Interactive discussion. Round table: The answers from the experts |
| 12.05 - 12.10 | Closure
S. Rusconi |
Oral Communications
Immunopathogenesis II
Oral Communications
Immunopathogenesis II
Chairs: V. Borghi, A. Callegaro
| 12.15 - 12.25 | OC 42 The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates the immunoregulatory/inflammatory signals
|
| 12.27 - 12.37 | OC 43 Detection of SARS-CoV-2 RNA and evaluation of neurofilament light chain in cerebrospinal fluid and plasma of COVID-19 patients
|
| 12.39 - 12.49 | OC 44 MMP-9 and TIMP-1 as a potential disease biomarker in patients with COVID-19 pneumonia
|
| 12.51 - 13.01 | OC 45 An NF-kB/Jak/Stat signaling pathways is involved in APOBEC3A induction following CCL2 neutralization in primary human macrophages
|
| 13.03 - 13.13 | OC 46 Oral mucosal immunity in SARS-CoV-2 infected and/or vaccined subjects
|
Oral Communications
Comorbidities II
Oral Communications
Comorbidities II
Chair: M. Borderi
| 14.15 - 14.25 | OC 49 Viral dynamics in cerebrospinal fluid of patients with Progressive Multifocal Leukoencephalopathy
|
| 14.27 - 14.37 | OC 50 Switching to INSTI offsets negative effects of weight gain on incidence of insulin resistance in people living with HIV
|
Oral Communications
Virology and Pharmacology II
Oral Communications
Virology and Pharmacology II
Chairs: S. Parisi, O. Turriziani
| 14.50 - 15.05 | An update on the pharmacological strategies in the treatment of viral infections
S. Bonora |
| 15.05 - 15.20 | Pharmacology as a tool for polypharmacy management in HIV
C. Gervasoni |
| 15.20 - 15.30 | OC 60 Evaluation of factors potentially associated with Low-level viremia in PLWH from the Italian ARCA cohort: a matched Case-Control Study
|
| 15.32 - 15.42 | OC 61 Distribution of tenofovir plasma trough concentrations in PLWH treated with doravirine
|
| 15.44 - 15.54 | OC 62 SNP-168 of the protein kinase and CD4 or CD8 dynamic in HIV-1 patients
|
| 15.56 - 16.06 | OC 63 Interpatient variability in the pharmacokinetics of the remdesivir and main metabolite GS-441524 in treated COVID-19 subjects
|
| 16.08 - 16.18 | OC 64 Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests on isolates with contextual undetectable HIV-1 plasma viral load performed for clinical routine
|
Special Session
Riunione operativa Fast-Track
Special Session
Riunione operativa Fast-Track
Meet the Community
Sex Check for Prep
Meet the Community
Sex Check for Prep
Chair: V. Puro
| 11.10 - 12.10 | Sex Check for Prep
S. Mattioli |
Oral Communications
Virology and Pharmacology I
Oral Communications
Virology and Pharmacology I
Chairs: D. Cattaneo, M. Santoro
| 14.15 - 14.25 | OC 51 Virological and Serological Characterization of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination
|
| 14.27 - 14.37 | OC 52 Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected
|
Oral Communications
Epidemiology/Social sciences IV
Oral Communications
Epidemiology/Social sciences IV
Chairs: P. Bonfanti, G. Verucchi
| 14.50 - 15.00 | OC 65 Interest in injecting Long-Acting agents by people living with HIV in Italy: a picture from the Icona Network
|
| 15.02 - 15.12 | OC 66 Milan Fast Track City: study on HIV prevalence in two different settings
|
| 15.14 - 15.24 | OC 67 Impact of COVID-19 on HIV testing and counselling services in Lazio Region
|
| 15.26 - 15.36 | OC 68 Estimation of the proportion of people living with HIV in ART and virally suppressed, using surveillance and cohort data. Italy, 2012-2019
|
| 15.38 - 15.48 | OC 69 Prevalence of HIV infection in the PIPSA project carried out in Luanda, Angola. Data analysis by sex and age group
|
| 15.50 - 16.00 | OC 70 High prevalence of mental health disorders in HIV positive adolescents and youths: an observational study from 8 health services in Beira district, Mozambique
|
| 16.02 - 16.12 | OC 71 High prevalence of asymptomatic Sars-Cov2 infection in the cohort of Liver Transplant Recipients at INMI Spallanzani
|
Promosso da
Con la sponsorizzazione non condizionante di 
Password dimenticata
Inserisca il suo indirizzo email. Riceverà un messaggio con il link per effettuare il reset della password.
